Latest news with #SanjeevPanchal
Business Standard
8 hours ago
- Business
- Business Standard
AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY
AstraZeneca Pharma surged 10.03% to Rs 8764.05 after the company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, "Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million)." The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
AstraZeneca Pharma Q4 FY25 net profit jumps 48% to Rs 58.25 crore
AstraZeneca Pharma India on Friday reported a 48 per cent rise in consolidated net profit for the fourth quarter ended 31 March to Rs 58.25 crore. Total revenue from operations stood at Rs 480.48 crore, up 25.3 per cent year-on-year. The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year. Profit before tax (PBT) stood at Rs 84.15 crore in Q4FY25, compared to Rs 54.36 crore in the same quarter last year. 'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent. This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet,' said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma India Limited. In its oncology business, the pharma major reported revenue of Rs 315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to Rs 122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24. 'We are pleased to share that our company has, for the first time, crossed the Rs 1,700 crore mark ($200 million). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society, and the planet,' said Sanjeev Panchal, Country President and Managing Director of the company. The Bengaluru-based pharmaceutical firm announced its results post-market hours. Shares of the company were trading at Rs 7,980 apiece, up 0.78 per cent on the NSE.
India Today
08-05-2025
- Health
- India Today
India expands use of AstraZeneca's drug for advanced breast cancer cases
AstraZeneca Pharma India has received approval from India's drug regulator to expand the use of a breast cancer treatment that could bring new hope to many women with advanced medicine, Trastuzumab deruxtecan, was already available for some breast and stomach it has been approved to treat more patients, specifically adults with HER2-low or HER2-ultralow metastatic breast cancer who have already tried hormone-based This approval by the Central Drugs Standard Control Organisation (CDSCO) means more patients in India with hard-to-treat breast cancers can access the IS HER2-LOW BREAST CANCER?HER2 is a protein found on the surface of some cancer cells. When levels of HER2 are high, certain targeted treatments can work. However, many patients have low or very low levels of this protein, these are known as HER2-low or HER2-ultralow recently, there were limited treatment options for these patients. But this drug offers a targeted approach even in those with lower HER2 SCIENCE BEHIND THE APPROVALThe decision is based on results from a large international study called DESTINY-Breast06, which compared Trastuzumab deruxtecan with standard trial involved patients who had already received at least one hormone therapy but no chemotherapy for their metastatic results were promising:Patients who took Trastuzumab deruxtecan lived longer without the disease getting those with HER2-low breast cancer, the average time without disease progression was 13.2 months, compared to 8.1 months for those on risk of disease progression or death was reduced by nearly 40%.Dr. Sandeep Arora, Director of Medical Affairs at AstraZeneca India, said, "This approval marks a shift in how we treat advanced breast cancer in India. It highlights the importance of testing tumors for even minimal HER2 expression to identify patients who may benefit."WHY THIS MATTERS IN INDIABreast cancer is the most commonly diagnosed cancer worldwide, with over 2 million cases in 2020, according to the World Health Organisation. In India, the number of breast cancer cases has risen by 40% in the past 25 Sanjeev Panchal, Managing Director of AstraZeneca India, called it part of a broader effort to "follow the science" and deliver better, more personalised cancer drug was first introduced in India in 2024 and is now approved for three types of breast and gastric cancers. Experts hope that with wider use, this medication could significantly improve survival rates for women with advanced breast say it will now be important to test tumors for HER2 expression, even at very low levels, to identify who could benefit from this not a cure, Trastuzumab deruxtecan represents another important step in making breast cancer treatment more precise and more effective for Indian patients.
